ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Baicalein-loaded nanocochleates for improving oral bioavailability: design, statistical optimization, and in vivo pharmacokinetic evaluation.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Baicalein, a naturally occurring flavonoid, exhibits potent lipoxygenase-inhibitory, anti-inflammatory, and immunomodulatory activities that are beneficial for treating osteoporosis. However, its poor aqueous solubility, low oral bioavailability, and extensive presystemic metabolism restrict its clinical applicability. Thus, the present work aimed to develop baicalein-loaded nanocochleates to improve its oral bioavailability. Baicalein-loaded nanocochleates were prepared from preformed liposomes using the trapping method and further statistically optimized using a 3-factor, 3-level Box-Behnken Design (BBD). The optimized batch showed a particle size of 230.53 ± 7.86 nm, a polydispersity index (PDI) of 0.39 ± 0.01, a zeta potential of -19.07 ± 1.21 mV, and an entrapment efficiency of 93.50 ± 1.32%. Further, DSC and ATR-FTIR results confirmed the successful encapsulation of baicalein within the lipid matrix of nanocochleates, while TEM images revealed elongated, rod-like nanocochleate structures. Importantly, the optimized formulation showed 88.59 ± 1.53% drug release over 24 h compared with baicalein-loaded liposomes (96.10 ± 7.03%), indicating sustained drug release. In vivo oral pharmacokinetic studies demonstrated a 1.49-fold and 11.50-fold increase in C
Indexed as
Identifiers
42825926What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.